Vaccine and Immunotherapy for Removable Pancreatic Cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests two different vaccines (GVAX and a mKRAS vaccine) given before and after surgery for pancreatic cancer. Both vaccines are combined with immunotherapy drugs to help your immune system fight the cancer. The goal is to see which vaccine works better and is safe for patients whose tumors can be removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a newly diagnosed pancreatic cancer that is confirmed by a biopsy.
- Your tumor can be removed with surgery, and your doctor agrees.
- You are willing to have a biopsy (tissue sample) of your tumor.
- You have not had any previous treatment for pancreatic cancer, including chemotherapy, radiation, or immunotherapy.
- You do not have an active autoimmune disease, uncontrolled infection, or other serious health conditions (like heart failure or lung disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cancer vaccine (ELI-002 7P) for people with pancreatic cancer that hasn't spread to other parts of the body. It may be given alone or with another drug (tislelizumab) that helps the immune system fight cancer. The goal is to see if these treatments can help keep the cancer from coming back after surgery or chemotherapy.
This trial tests a cancer vaccine designed to target KRAS-mutated tumors, combined with two immunotherapy drugs, for people with advanced colorectal or pancreatic cancer. It may help the immune system recognize and attack cancer cells.
This study tests a personalized vaccine made from your own tumor, combined with a drug that helps your immune system fight cancer cells. The goal is to see if this approach can help prevent your pancreatic cancer from coming back after surgery.
This trial tests giving a combination of an oncolytic virus, immunotherapy (PD-1 inhibitor), and chemotherapy before surgery to shrink pancreatic tumors and make them easier to remove. The goal is to improve outcomes for people with borderline resectable or locally advanced pancreatic cancer.
This trial tests a personalized neoantigen vaccine given along with an anti-PD1 drug (pembrolizumab) and chemotherapy after surgery for pancreatic cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This trial tests a new treatment that combines a cancer-killing virus with an immunotherapy drug (a PD-1 inhibitor) for advanced pancreatic cancer. It aims to see if this combination can help shrink tumors and improve outcomes for patients who have already tried chemotherapy.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.